Adare Pharmaceuticals

Oral Drug Delivery Technologies and Drug Development

Adare Pharmaceuticals Opens New Corporate Headquarters

Adare Pharmaceuticals has officially opened a new corporate headquarters at 1200 Lenox Drive in Lawrenceville, New...

Adare Pharmaceuticals Opens New Corporate Headquarters

Adare Pharmaceuticals to Present at BIO International

Global specialty pharmaceutical company Adare Pharmaceuticals will present its company overview at the BIO International Convention in...

Adare Pharmaceuticals to Present at BIO International

Allegra Dry Syrup 5% Launches in Japan

Sanofi K.K has announced that Allegra dry syrup 5% has launched in...

Allegra Dry Syrup 5% Launches in Japan

Forest Laboratories to Acquire Aptalis

Aptalis has signed a definitive agreement to be acquired by Forest Laboratories, a leading, fully integrated, specialty pharmaceutical company, for $2.9bn in cash pending required...

Forest Laboratories to Acquire Aptalis

Aptalis Pharmaceutical Technologies Co-Sponsors 2013 Controlled Release Society's Young Investigator Award at 40th Annual Meeting and Exposition

Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that focuses on developing patient-optimised oral products utilising its proprietary pharmaceutical technologies...

Aptalis Pharmaceutical Technologies Co-Sponsors 2013 Controlled Release Society's Young Investigator Award at 40th Annual Meeting and Exposition

Aptalis Pharmaceutical Technologies Expands Licensing Team

Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that develops differentiated products utilizing its oral delivery technologies, today announces that Nigel Ray has been...

Aptalis Pharmaceutical Technologies Expands Licensing Team

Aptalis Releases Two Free White Papers

Aptalis Pharmaceutical Technologies has released two free white papers on Pharmaceutical Technology....

Aptalis Releases Two Free White Papers

Aptalis Announces European Commission Approval for New Formulation of Viread®

Aptalis Pharmaceutical Technologies, formerly Eurand Pharmaceutical Technologies, focused on developing differentiated oral products utilising its pharmaceutical technologies, today announced...

Aptalis Announces European Commission Approval for New Formulation of Viread®

PharmaTelevision Interview to Spotlight Aptalis Pharma’s Year in Review

FDA approvals, revenue gain and organic business growth are just a few of the topics that Aptalis Pharma president John Fraher addresses during an on-air interview with PharmaVentures...

PharmaTelevision Interview to Spotlight Aptalis Pharma’s Year in Review

Aptalis Pharmaceutical Technologies Sponsors 2012 Controlled Release Society's Young Investigator Award

Aptalis Pharmaceutical Technologies has announced its co-sponsorship of the Controlled Release Society's Young Investigator Award and its participation in the 39th Annual Meeting & Exposition...

Aptalis Pharmaceutical Technologies Sponsors 2012 Controlled Release Society's Young Investigator Award